相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Stephanie Kullmann et al.
DIABETES CARE (2022)
Insulin Resistance: From Mechanisms to Therapeutic Strategies
Shin-Hae Lee et al.
DIABETES & METABOLISM JOURNAL (2022)
Lean insulin-resistant young adults display increased cardiometabolic risk: A retrospective cross-sectional study
Katarina Sebekova et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Stephanie Kullmann et al.
DIABETES CARE (2022)
Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial
Lin Yang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
Tian Li et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Lorenzo Nesti et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats
Nora El-Sayed et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2021)
Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial
Giuseppe Della Pepa et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective
Maria G. Tinajero et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2021)
Insulin resistance and insulin sensitizing agents
Lucia Mastrototaro et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai-Fan Tsai et al.
ANTIOXIDANTS (2021)
Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice
Tuo Han et al.
ADIPOCYTE (2021)
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Enxiang Zhang et al.
HEPATOLOGY COMMUNICATIONS (2021)
Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis
Kui Zhang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tanase et al.
JOURNAL OF DIABETES RESEARCH (2020)
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus
Karen E. Elkind-Hirsch et al.
AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY MFM (2020)
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
Ralph A. DeFronzo et al.
DIABETES & VASCULAR DISEASE RESEARCH (2019)
Effects of Magnesium Deficiency on Mechanisms of Insulin Resistance in Type 2 Diabetes: Focusing on the Processes of Insulin Secretion and Signaling
Krasimir Kostov
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Metformin in 2019
James Flory et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis
Yechen Han et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Type 2 diabetes: a multifaceted disease
Ewan R. Pearson
DIABETOLOGIA (2019)
Biomarkers for type 2 diabetes
Markku Laakso
MOLECULAR METABOLISM (2019)
High glucose inhibits myogenesis and induces insulin resistance by downregulating AKT signaling
Wei Luo et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study
Daniel I. Bromage et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Insulin resistance: Review of the underlying molecular mechanisms
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes
Yury O. Nunez Lopez et al.
MOLECULAR METABOLISM (2019)
Cardiovascular Effects of New Oral Glucose-Lowering Agents DPP-4 and SGLT-2 Inhibitors
Andre J. Scheen
CIRCULATION RESEARCH (2018)
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Meng Lee et al.
STROKE (2017)
Neuronal control of peripheral insulin sensitivity and glucose metabolism
Johan Ruud et al.
NATURE COMMUNICATIONS (2017)
Insulin Resistance, Type 1 and Type 2 Diabetes, and Related Complications 2017
Joseph Fomusi Ndisang et al.
JOURNAL OF DIABETES RESEARCH (2017)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Simon J. Griffin et al.
DIABETOLOGIA (2017)
Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity
Christos N. Joannides et al.
DIABETES OBESITY & METABOLISM (2017)
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
Fumika Shigiyama et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
Silvio E. Inzucchi et al.
DIABETES CARE (2016)
REVISITING THE USE OF PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES
Daniel Einhorn et al.
ENDOCRINE PRACTICE (2016)
Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease
Panu K. Luukkonen et al.
JOURNAL OF HEPATOLOGY (2016)
An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
Yaowen Wang et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
James D. Lewis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity A cross-sectional analysis of the RISC Study
Simona Baldi et al.
DIABETES CARE (2013)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
Markolf Hanefeld et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials
C. Lamanna et al.
DIABETES OBESITY & METABOLISM (2011)
Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes
G. Derosa et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial
Kohei Kaku
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM
Alfonso Perez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes
G. Derosa et al.
DIABETES OBESITY & METABOLISM (2009)
Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes
Kazuo Eguchi et al.
HYPERTENSION RESEARCH (2007)
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review
A Natali et al.
DIABETOLOGIA (2006)
A fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic control
Jochen Seufert
CURRENT MEDICAL RESEARCH AND OPINION (2006)
分享论文
